We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

MK0767 Added to Insulin Therapy in Patients With Type 2 Diabetes (0767-030)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00543816
Recruitment Status : Terminated
First Posted : October 15, 2007
Last Update Posted : June 23, 2015
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:

This study will look to see if MK0767 works better than placebo in controlling blood sugar in patients with Type 2 Diabetes who are taking insulin but do not have adequate control of their blood sugar.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 2 Drug: MK0767 Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Study Start Date : August 2003
Primary Completion Date : November 2003
Study Completion Date : November 2003

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type 2 Diabetes with inadequate glycemic control
  • Patient is on stable insulin therapy alone or with one oral antidiabetic agent
  • Male or non-pregnant female 21 years or older
  • Total daily dose of insulin must be less than or equal to 30 but not greater than or equal to 200 units/day

Exclusion Criteria:

  • Have a history of type 1 diabetes mellitus
  • History of ketoacidosis who are being treated with insulin
  • Are taking 2 or more antidiabetic agents in combination with insulin

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00543816

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Study Director: Medical Monitor Merck Sharp & Dohme Corp.

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00543816     History of Changes
Other Study ID Numbers: 0767-030
First Posted: October 15, 2007    Key Record Dates
Last Update Posted: June 23, 2015
Last Verified: June 2015

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases